Policy: MBP 139.0
Section: Medical Benefit Pharmaceutical Policy
Subject: Darzalex (daratumumab)

I. Policy:
Darzalex (daratumumab)

II. Purpose/Objective:
To provide a policy of coverage regarding Darzalex (daratumumab)

III. Responsibility:
A. Medical Directors
B. Medical Management
C. Pharmacy Department

IV. Required Definitions
1. Attachment – a supporting document that is developed and maintained by the policy writer or department requiring/authoring the policy.
2. Exhibit – a supporting document developed and maintained in a department other than the department requiring/authoring the policy.
3. Devised – the date the policy was implemented.
4. Revised – the date of every revision to the policy, including typographical and grammatical changes.
5. Reviewed – the date documenting the annual review if the policy has no revisions necessary.

V. Additional Definitions
Medical Necessity or Medically Necessary means Covered Services rendered by a Health Care Provider that the Plan determines are:

a. appropriate for the symptoms and diagnosis or treatment of the Member's condition, illness, disease or injury;
b. provided for the diagnosis and the direct care and treatment of the Member's condition, illness disease or injury;
c. in accordance with current standards good medical treatment practiced by the general medical community;
d. not primarily for the convenience of the Member, or the Member's Health Care Provider; and
e. the most appropriate source or level of service that can safely be provided to the Member. When applied to hospitalization, this further means that the Member requires acute care as an inpatient due to the nature of the services rendered or the Member's condition, and the Member cannot receive safe or adequate care as an outpatient.

Medicaid Business Segment
Medical Necessity shall mean a service or benefit that is compensable under the Medical Assistance Program and if it meets any one of the following standards:

(i) the service or benefit will, or is reasonably expected to, prevent the onset of an illness, condition or disability.
(ii) the service or benefit will, or is reasonably expected to, reduce or ameliorate the physical, mental or development effects of an illness, condition, injury or disability.
(iii) the service or benefit will assist the Member to achieve or maintain maximum functional capacity in performing daily activities, taking into account both the functional capacity of the Member and those functional capacities that are appropriate for members of the same age.
DESCRIPTION:
Darzalex (daratumumab) is an IgG1κ human monoclonal antibody directed against CD38. CD38 is a cell surface glycoprotein which is highly expressed on myeloma cells, yet is expressed at low levels on normal lymphoid and myeloid cells (Lokhorst 2015). By binding to CD38, daratumumab inhibits the growth of CD38 expressing tumor cells by inducing apoptosis directly through Fc mediated cross linking as well as by immune-mediated tumor cell lysis through complement dependent cytotoxicity, antibody dependent cell mediated cytotoxicity, and antibody dependent cellular phagocytosis.

CRITERIA FOR USE: Requires Prior Authorization by Medical Director or Designee

Darzalex (daratumumab) will be considered medically necessary when all of the following criteria are met:

- Prescription written by a hematologist/oncologist AND
- Medical record documentation a diagnosis of multiple myeloma AND

If newly diagnosed multiple myeloma (transplant ineligible):

- Medical record documentation that the member is not eligible for stem-cell transplantation (e.g. coexisting conditions, age greater than 65, etc.) AND
- Medical record documentation that Darzalex will be given in combination with one of the following options:
  - Bortezomib (Velcade), melphalan, AND prednisone [VMP] OR
  - Lenalidomide (Revlimid) AND dexamethasone

If newly diagnosed multiple myeloma (transplant eligible):
- Medical record documentation that the member is eligible for stem-cell transplantation AND
- Medical record documentation that Darzalex will be given in combination with bortezomib (Velcade), thalidomide, and dexamethasone (DVTd)

OR

If relapsed/refractory multiple myeloma:

- One of the following:
  - Medical record documentation of therapeutic failure on, intolerance to, or contraindication to at least three prior lines of therapy including a proteasome inhibitor (including but not limited to Velcade*, Kyprolis*, or Ninlaro*) and an immunomodulatory agent (including but not limited to Pomalyst*, Revlimid*, Thalomid*) OR
  - Medical record documentation that the patient is double-refractory to a proteasome inhibitor (including but not limited to Velcade*, Kyprolis*, or Ninlaro*) and an immunomodulatory agent (including but not limited to Pomalyst*, Revlimid*, Thalomid*) OR
  - Medical record documentation of therapeutic failure on, intolerance to, or contraindication to at least 1 prior therapy including a proteasome inhibitor (including but not limited to Velcade*, Kyprolis*, or Ninlaro*) or an immunomodulatory agent (including but not limited to Pomalyst*, Revlimid*, Thalomid*) AND one of the following:
    - Medical record documentation that Darzalex will be prescribed in combination with lenalidomide and dexamethasone OR
    - Medical record documentation that Darzalex will be prescribed in combination with bortezomib and dexamethasone

AUTHORIZATION DURATION: Initial approval will be for 12 months or less if the reviewing provider feels it is medically appropriate. Subsequent approvals will be for an additional 12 months or less if the reviewing provider feels it is medically appropriate and will require medical record documentation of continued disease improvement or lack of disease progression. The medication will no longer be covered if patient experiences toxicity or worsening of disease.

LINE OF BUSINESS:
Eligibility and contract specific benefit limitations and/or exclusions will apply. Coverage statements found in the line of business specific benefit document will supersede this policy.

This policy will be revised as necessary and reviewed no less than annually.

Devised: 1/19/2016

Revised: 1/17/17 (updated indication), 7/17/18 (updated indication), 9/17/19 (updated indication), 11/19/19 (transplant status)

Reviewed: 10/28/16, 10/31/17, 5/31/19